GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.
GSK · GSK plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
GSK plans to deliver 1.9 billion of costs by 29 through restructuring across its value chain, with most of the savings reinvested in R&D. It also says it will not slow down on BD.
GSK plc reports that Hal Barron, James Ford and Maya Martinez-Davis acquired American Depositary Shares via dividend reinvestment in executive savings plan accounts on 2026-11-13 at $50.4500.
GSK plc announced CHMP recommended updating the Bexsero label for a single booster dose in individuals aged 10 years and older vaccinated at least two years earlier. Men-B-096 met its primary endpoint, showing immune memory from infant vaccination can be boosted up to 19 years later.
GSK plc disclosed that Lynn Baxter and other executives or a PCA acquired ordinary shares under the Share Reward Plan at £19.3453 on 2026-11-10. Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 on 2026-11-09.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GSK
this stock
GSK plc
|
$97.38B | -0.9% | — | — | 0.8% |
|
LLY
ELI LILLY & Co
|
$1.30T | +28.7% | +44.7% | 44.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$656.47B | +31.8% | +6.0% | 41.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$505.56B | +25.2% | +8.6% | 49.2 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$339.66B | +30.9% | +1.3% | 142.0 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 240
GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GSK | -4.0% | -2.9% | -3.9% | -1.9% | -0.9% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -0.1% | +2.7% | -0.4% | +1.5% | -8.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.